Alcon Inc. reports developments in eye care through its Surgical and Vision Care businesses. Company news commonly covers quarterly results, constant-currency sales trends, product-launch momentum and portfolio updates across cataract and vitreoretinal surgical systems, intraocular lenses, contact lenses, lens-care products and ocular health.
Recurring updates also include launches and milestones for products such as Clareon, PanOptix, Vivity, TOTAL30, Precision7, Tryptyr and Unity, along with annual general meeting items, board elections, compensation votes, dividends, share repurchase authorizations, acquisitions, integration costs, R&D spending and other governance or capital-allocation actions.
Alcon (NYSE: ALC), a leader in eye care, will host its 2023 Capital Markets Day on March 30, 2023, starting at 8:00 a.m. CT. The event will feature key updates and strategic insights, accessible via a live webcast at investor.alcon.com.
With over 75 years of history, Alcon offers a vast portfolio of surgical and vision care products, improving the lives of over 260 million people annually across 140 countries. Their commitment to enhancing quality of life through innovative eye care solutions is pivotal in addressing conditions like cataracts and glaucoma.
Alcon has launched TOTAL30 for Astigmatism, the first reusable Water Gradient toric lens, now available to U.S. Eye Care Professionals. This lens enhances comfort and mimics the ocular surface structure, addressing the needs of the growing astigmatic market. Alcon also showcases its expanded toric lens portfolio, including DAILIES TOTAL1 and PRECISION1 for Astigmatism, at the SECO International meeting in Atlanta. Clinical data presentations will highlight the efficacy of its vision care and dry eye products. Alcon's ongoing commitment to innovation aims to improve patient care and comfort in the ocular health sector.
Alcon reported fourth quarter 2022 sales of $2.2 billion, up 1% year-over-year, or 7% on a constant currency basis. For full-year 2022, sales reached $8.7 billion, a 5% increase, with diluted EPS at $0.68, down 11%, but up 37% in constant currency. Key segments included Surgical sales of $1.3 billion, a 1% increase, and Vision Care sales of $0.9 billion, up 1%. The company expects mid-to-high single-digit sales growth and high teens earnings growth for 2023, with a proposed dividend of CHF 0.21 per share subject to shareholder approval.
Alcon, a leader in eye care, has reached a settlement with J&J Surgical Vision, Inc. to resolve ongoing legal disputes over femtosecond laser assisted cataract surgery devices, particularly the LenSx® device. As part of this agreement, Alcon will pay USD 199 million to J&J for cross-licenses of certain intellectual property and to settle various worldwide intellectual property disputes. This settlement aims to mitigate legal uncertainties and enhance Alcon's operational focus, allowing it to continue its mission to improve global eye care.
Alcon (SIX/NYSE: ALC) has announced the launch of TOTAL30 for Astigmatism and DAILIES TOTAL1 for Astigmatism in Canada, expanding its range of innovative contact lenses for astigmatic patients. As the toric lens segment is rapidly growing, with only 10% of the 47% of patients needing correction currently using toric lenses, this launch addresses a significant market gap. The lenses utilize Alcon's proprietary Water Gradient technology, providing enhanced comfort and moisture retention. With added features like PRECISION BALANCE 8|4 lens design and CELLIGENT™ Technology, these products aim to improve wearers' experiences significantly.
Alcon (NYSE: ALC) has announced the launch of TOTAL30® for Astigmatism, the first reusable contact lens utilizing Water Gradient technology for astigmatic wearers. This innovative product enhances comfort and visual stability, targeting the $1.2 billion reusable toric lens market. Available in the U.S. and Europe from early 2023, TOTAL30 aims to improve the lens-wearing experience for astigmatic patients. The product features biomimetic CELLIGENT™ Technology to resist bacteria, ensuring a cleaner lens throughout the month.
Alcon (NYSE: ALC) CEO David Endicott will present at the 2023 J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 11:15 a.m. PST. A live webcast of the presentation will be available at investor.alcon.com/news-and-events/events-and-presentations. As a global leader in eye care, Alcon serves over 260 million people with products for conditions such as cataracts and glaucoma, emphasizing its commitment to enhancing sight and quality of life.
Alcon Inc. ('ALC') has launched a private offering of US$700 million in 5.375% senior notes due 2032 and US$600 million in 5.750% senior notes due 2052. The offering is set to close on December 6, 2022. Proceeds will be directed towards general corporate purposes, including repaying outstanding debts related to its acquisition of Aerie Pharmaceuticals, Inc. The notes will be issued by Alcon Finance Corporation and guaranteed by Alcon.
Alcon has successfully completed its acquisition of Aerie Pharmaceuticals for approximately $930 million. This acquisition strengthens Alcon's position in the $20 billion global ophthalmic pharmaceutical market, enhancing its product offerings with Rocklatan and Rhopressa, and adding AR-15512, a Phase 3 dry eye candidate. The deal will leverage Alcon’s commercial capabilities and expand its research and development expertise, supporting future growth. Alcon aims to fully integrate Aerie into its operations, building on previous acquisitions to enhance its ophthalmic pharmaceutical portfolio.
Alcon reported third quarter 2022 sales of $2.1 billion, reflecting a 2% increase year-over-year and a 9% rise in constant currency. Diluted earnings per share were $0.23, while core earnings per share were $0.50, down 7% on a reported basis but up 14% in constant currency. The updated 2022 outlook expects net sales between $8.5 billion and $8.7 billion, with a core operating margin tightening to 18.0%-18.5%. Challenges include foreign currency impacts and supply chain issues. The acquisition of Aerie Pharmaceuticals is anticipated to close in Q4 2022.